Conditions: Pain Bladder Cancer Breast Cancer CNS Cancer Colon Cancer Esophageal Cancer Pancreatic Cancer Prostate Cancer Uterine Cancer Head and Neck Cancer Eye Cancer Otorhinolaryngologic Neoplasms
Keywords: Pain HEENT cancer
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 10
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain. Patients are being asked to participate in the Phase I portion of this study.

Detailed description:

Arms:
arm 1: This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours. arm 2: patients receiving around the clock opioid therapy-No patients were accrued to this group arm 3: patients not receiving around the clock opioid therapy.No patients were accrued to this group

Interventions: intervention 1: d-Methadone intervention 2: D-methadone intervention 3: placebo
Intervention descriptions: intervention 1: 8 subjects to receive 40 mg d-Methadone twice a day intervention 2: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24. intervention 3: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.

Protocol document: